JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2022

Primary Completion Date

August 16, 2026

Study Completion Date

December 16, 2026

Conditions

Glioblastoma Multiforme (GBM)

Interventions

DRUG

JK-1201I

JK-1201I will be administered.

DRUG

Temozolomide (TMZ)

Temozolomide will be administered.

Trial Locations (1)

RECRUITING

Beijing Tiantan Hospital, Beijing

All Listed Sponsors

lead

JenKem Technology Co., Ltd.

INDUSTRY